Hyderabad, October 5: Sai Parenterals Limited, a leading pharmaceutical manufacturer, has completed the acquisition of a 60% stake in Hyderabad-based Prathyak Laboratories Private Limtied for ₹15 crore. This investment is aiemd to accelerate Sai Parenterals formulation and contract development capabilities, directly boosting its commercial production pipeline for injectable drugs for the regulated global markets.
Under the terms of the transaction, Sai Parenterals will acquire 60% in Prathyak Labs, with an option to buy the residual 40% through a Right of First Refusal (ROFR) at the same value, eventually making Prathyak Labs a wholly owned subsidiary. This R&D lab brings 28 research scientists and a development pipeline of 150 SKUs across 86 molecules, as it looks to build its base in complex injectables and in oncology injectables.
“Building a research centre from the ground up would have cost us a construction cycle and, far more significantly, the time taken to assemble a scientific team. Prathyak gives us both on day one — 28 research scientists who have worked together for three years, and a pipeline of 150 SKUs across 86 molecules in exactly the complex injectable and oncology areas we are building towards.
The value of this acquisition lies in what it enables elsewhere in the Group. Work already completed at this R&D centre can be taken into production as our injectable capacity is expanded. The same R&D team will also develop the new products we are required to launch each year under our Australian agreements. We have acquired 60% today and will move to full ownership at the same valuation.
This is a further step in the growth plan we set out at the time of our listing: deeper integration across our own value chain, a faster route from development to commercial supply, and capability built inside the Group instead of with third parties. We will continue to pursue opportunities of this kind, organic and inorganic, that strengthen the platform and create lasting value for our stakeholders,” Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said in a press release.
